Pharmaceutical Distribution in Europe Market Intelligence

Pharmaceutical Distribution in Europe Market Description

Among the 13 countries of Western and Southern Europe, the highest recent pharmaceutical wholesale sales were noted in the U.K. with sales worth €11,260 million, followed by Germany with €27,168 million sales and Spain with €8,909 million sales. From the 15 Central and Eastern Europe nations, the maximum pharmaceutical wholesale sales were in Poland with €5,741 million, followed by Latvia with €2,916 million and then Greece with €2,792 million. The largest wholesaler margin in the entire Europe region is in Denmark with a 7-20 percent margin.

The report provides a comprehensive overview of the pharmaceutical distribution market in 13 countries of Western and Southern Europe and 15 countries in Central and Eastern Europe. For each country under consideration, the report identifies the pharmaceutical wholesale distribution dynamics, top 3 pharmaceutical wholesalers for each country and the overall pharmacy landscape. The report examines the engagement model, pricing model and wholesaler/distribution margin used in the pharmaceutical distribution market in each of the individual countries. The report also identifies the relevant licensing authorities and sales incentives for the pharmaceutical distribution market in the concerned countries.

Beroe gathers intelligence through primary sources that include industry experts, researchers, and consultants, as well as current suppliers, producers and distributors. Secondary sources can include business journals, newsletters, magazines, market research data, company sources, and industry associations. Following data collation, analysis, and strategic review, the Final Research Report is published on Beroe LiVE.

Report Coverage

Pharma Distribution: Latvia
Pharma Distribution: Lithuania
Pharma Distribution: Poland
Pharma Distribution: Romania
Pharma Distribution: Serbia

Pharmaceutical Distribution in Europe Market Trend, Analysis & Forecast

Category Intelligence on Pharmaceutical Distribution in Europe covers the following

Information relating to market, supply, cost, and pricing analysis
Hard to find data on cost and TCO models, supplier details, and performance benchmarks
Macroeconomic and regional trends impacting cost, supply, and other market dynamics
Category-specific negotiation and sourcing advice

icon
Executive Summary

icon
Market Analysis

icon
Supply Analysis

icon
Cost & Pricing Analysis

icon
Best Practices

Executive Summary
Western and Southern Europe
Pharma Distribution: Austria
Pharma Distribution: Belgium
Pharma Distribution: Denmark
Pharma Distribution: Italy
Pharma Distribution: The Netherlands
Pharma Distribution: Norway
Pharma Distribution: France
Pharma Distribution: Germany
Pharma Distribution: Portugal
Pharma Distribution: Spain
Pharma Distribution: Switzerland
Pharma Distribution: UK
Pharma Distribution: Ireland
Pharma Distribution: Bosnia Herzegovina
Pharma Distribution: Bulgaria
Pharma Distribution: Croatia
Pharma Distribution: Czech Republic
Pharma Distribution: Estonia
Pharma Distribution: Greece
Pharma Distribution: Hungary
Pharma Distribution: Kosovo
Pharma Distribution: Latvia
Pharma Distribution: Lithuania
Pharma Distribution: Poland
Pharma Distribution: Romania
Pharma Distribution: Serbia
Pharma Distribution: Slovakia
Pharma Distribution: Slovenia

Regional Market Outlook on Pharmaceutical Distribution in Europe

Pharma Distribution: Austria

Industry is expected to have low bargain and negotiation power, as the pricing mechanism is regulated (average margin of 10 percent) and a consolidated supply market (the top three wholesaler’s share is about 77 percent).General practice is to engage with a single wholesaler; however, international manufacturers deal with more than one wholesaler, based on the product portfolio.

Engagement Model

Single wholesaler for pharmaceutical products is usually adopted
Majority of the pharmaceutical distribution is through the channel of full-line wholesalers

Distribution Services

Fee for service is the prevalent pricing model
Pharmaceutical companies are charged on a fixed commission basis by pharmaceutical wholesalers

Wholesaler/Distribution Margin

The average margin for wholesalers is 10 percent

Sales Incentives

Non-monetary incentives include training and business education

Pharma Distribution: The Netherlands

Industry is expected to have medium bargain and negotiation power, as the pricing mechanism is negotiable by wholesalers (average margin of 8–12 percent), with a fragmented supply market (the top two wholesaler’s share is 40–45 percent).Distribution to hospitals happens through either wholesalers or directly by manufacturers. For direct distribution to hospitals, pharmaceutical companies use wholesaler as logistics service providers.

Engagement Model

Manufacturers engage with one to two full-line wholesalers for the distribution of products, and the minimum contract period of engagement is three years
Wholesalers act as a pre-wholesaling distribution partner for direct DTP and hospitals

Distribution Services

Fee for service is the preferred pricing model

Wholesaler/Distribution Margin

Wholesaler’s margin is unregulated and has no statutory markups on wholesale level, like other EU countries. Wholesalers have entered into a private negotiation with manufacturers
Wholesaler’s margin is 8.5–11.8 percent.

Sales Incentives